Compounded semaglutide
Sold by JRNYS · Injection · device not recorded · every compounded semaglutide record
The program identifies an injection, but the delivery device has not been established.
Price
| Term | Published rate | Charged today |
|---|---|---|
| Compounded semaglutide advertised starting price Price conditions have not been established; the quoted figure is not a verified recurring rate. Advertised starting amount; prescribed dose, quantity and initial invoice are not established. “JRNYS compounded semaglutide starts at $199/month. No insurance required.” | $199Published figure | Charged todayNot verified |
Price sources
- Compounded semaglutide advertised starting price · jrnys.com — read October 2026
We earn nothing from this link. It opens JRNYS's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
Sourcing and terms
| Pharmacy | Not disclosed |
|---|---|
| States | Not disclosed |
| Prescriber | Both |
| Cancellation | Cancel through the dashboard or support at least seven days before the next billing cycle. The cancellation page promises prorating with longer notice, while terms contain competing bracketed prorating/nonrefund clauses. Initial reviewed telehealth fee is listed as $89 in cancellation policy and $35 in terms; amount and additional-fee status remain unresolved. Shipped medical products cannot be returned. Appointment cancellation within 24 hours or a no-show can incur $25. https://jrnys.com/cancellation-policy https://jrnys.com/terms-and-conditions |
| Membership | Required. $89 per month. Product page says membership from $89/month and medication priced separately; final coaching tier and promotion eligibility unverified. |
| Consult fee | Included in program price; itemized amount is not published. Membership includes medical visits; initial fee refund amount conflicts in legal pages. |
Recorded from jrnys.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. October 2026 — Membership starts at $89/month and ranges to $169 with coaching support; medication is separate on the brand and compounded semaglutide pages. A JRNY50 banner offers 50% off the first membership month, but selected-plan eligibility and final invoice were not established, so no discounted fee is calculated. https://jrnys.com/weight-loss/product/ozempic
- 2. October 2026 — Public terms describe video, telephone and electronic-mail consultations, with provider review and messaging on product pages. No program-specific served-state roster or named dispensing pharmacy was established; local pharmacy choice and delivery are possible. https://jrnys.com/terms-and-conditions
- 3. October 2026 — Cancel through the dashboard or support at least seven days before the next billing cycle. The cancellation page promises prorating with longer notice, while terms contain competing bracketed prorating/nonrefund clauses. Initial reviewed telehealth fee is listed as $89 in cancellation policy and $35 in terms; amount and additional-fee status remain unresolved. Shipped medical products cannot be returned. Appointment cancellation within 24 hours or a no-show can incur $25. https://jrnys.com/cancellation-policy https://jrnys.com/terms-and-conditions
- 4. October 2026 — A dedicated commercial page explicitly names compounded semaglutide from $199/month, separately from membership. The Wegovy-page FAQ explicitly describes the compounded treatment as a weekly injection; a product image is not treated as proof of a specific vial/device. https://jrnys.com/weight-loss/product/compounded-semaglutide-2 https://jrnys.com/weight-loss/product/wegovvy
11 further notes concern other JRNYS programs and sit on the provider record.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.